In order to streamline operations and to facilitate the company’s entry into biologics within dermatology, LEO Pharma plans to restructure the organisation.

The plans involve restructuring the global organisation and outsourcing functions, which may lead to up to 400 positions ceasing to exist within the next year. Suggested reductions are expected to affect the commercial organisation, production and support functions in the global organisation.

At the same time, LEO Pharma says it intends to create up to 200 new positions to support the company’s entry into biologics within dermatology.

“Within the last year, we have made acquisitions and partnerships that have fundamentally changed LEO Pharma as a company and brought us much closer to fulfilling our vision of becoming the pre-ferred dermatology care partner. We are building a unique portfolio of treatment solutions in major skin diseases – and to realise their full potential, we need to invest and bring in new competences. At the same time, we need to continuously optimise operations and reduce costs where possible. We deeply regret that good colleagues may lose their jobs as part of this process,” says Gitte Aabo, President and CEO of LEO Pharma.

Future investments include launching the company’s first biologic treatment for psoriasis, launching a topical psoriasis treatment on new markets, supporting continued growth of the dermatology portfolio acquired from Astellas and conducting the clinical development of a biologic treatment for atopic dermatitis.